Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples